Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase Not Applicable
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Live Biobank — Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.

Primary Outcomes

  • establish a live biobank for breast cancer patients (60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-01-12
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Principal Investigators:
  • Silvia Formenti, M.D. (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Fabiana Gregucci, M.D.
646-962-3110
fgr4002@med.cornell.edu
Izael Niño, M.S.
929-470-9426
izn4001@med.cornell.edu
Brooklyn Methodist Hospital - NewYork Presbyterian
Hani Ashamalla, M.D.
Brooklyn Methodist Hospital - NewYork Presbyterian
Interventions
  • Procedure: Live Biobank — Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
Study Locations (2 sites)
Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York 11215 United States
New York Presbyterian Hospital - Queens, New York, New York 11355 United States
Eligibility Criteria
Inclusion Criteria: * All patients will historically proven BC are eligible to be on the study Exclusion Criteria: * Carriers of other cancers other than breast.

Topical Insulin for Glaucoma

NCT05206877
Recruiting
Conditions Glaucoma
Phase PHASE1
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Insulin, 4 units — Topical insulin 100 U/ml, 1 drop per day
  • Drug: Insulin, 20 units — Topical insulin 500 U/ml, 1 drop per day
  • Drug: insulin, 4 units twice daily — 1 drop of low dose insulin twice daily.
  • Drug: insulin, 20 units twice daily — 1 drop of high dose insulin twice daily
  • Drug: insulin, 4 units three times daily — 1 drop of low dose insulin three times daily.
  • Drug: insulin, 20 units three times daily — 1 drop of high dose insulin three times daily.

Primary Outcomes

  • Number of Participants with Treatment-Related Adverse Events (During treatment period, difference from baseline to post-treatment up to 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-04-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Jeffrey L Goldberg, MD, PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Mariana Nunez, MD
650-497-7846
mnunez1@stanford.edu
Zac Wennberg-Smith
zacwenn@stanford.edu
Byers Eye Institute at Stanford University
Interventions
  • Drug: Insulin, 4 units — Topical insulin 100 U/ml, 1 drop per day
  • Drug: Insulin, 20 units — Topical insulin 500 U/ml, 1 drop per day
  • Drug: insulin, 4 units twice daily — 1 drop of low dose insulin twice daily.
  • Drug: insulin, 20 units twice daily — 1 drop of high dose insulin twice daily
  • Drug: insulin, 4 units three times daily — 1 drop of low dose insulin three times daily.
Study Locations (1 sites)
Byers Eye Institute at Stanford University, Palo Alto, California 94303 United States
Eligibility Criteria
Inclusion Criteria: * Capable to provide informed consent * Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen. * Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched. Exclusion Criteria: * Pregnant or breastfeeding woman * Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.) * Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus * Inability to perform reliable visual field * Unable to provide informed consent * Unable to complete the tests and follow-ups required by the study
Conditions Type II Diabetes Mellitus, Efficacy, Sel...
Phase PHASE4
Enrollment 2000
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population. Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study. Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any). Follow up visits: After recruitment, patient is supposed to have three visits for follow-ups. Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy. LABORATORY TESTING: Reputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R/E. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations. Where in Urine Routine Examination (Urine R/E), we consider as follows: * Visual Examination: * Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other. * Urine clarity: Clear, slightly Cloudy, cloudy or turbidity * Chemical Examination: * Specific gravity * pH * Bilirubin * Urobilinogen * Protein * Ketone * Leukocyte Esterase * Microscopic Examination: * Red Blood Cells: * Epithelial Cells: * Amorphous: * Pus Cells * Bacteria * Yeast * Casts * Crystals Where in Renal Function Test (RFT), we consider as follows: * Blood Urea Nitrogen (BUN): mg/dL * Serum Creatinine: mg/dL * Estimated Glomerular Filtration Rate (eGFR): mL/min/1.73 m2

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Empagliflozin — Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg

Primary Outcomes

  • SAFETY and TOLERABILITY Outcomes (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-04-01
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Getz Pharma
Principal Investigators:
  • Umar Wahab (PRINCIPAL_INVESTIGATOR) - Umar Diabetes Foundation
Contact Information
Study Contact:
Dr. Muhammad Nabeed Tahir
+923015376299
nabeedt@gmail.com
Dr. Umar Wahab
+923339158285
dromarwahab@yahoo.com
Dr. Saira Banu Sokwalla
Agha Khan univeristy hospital
Interventions
  • Drug: Empagliflozin — Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
Study Locations (6 sites)
Kabul University of Medical Sciences(KUMS), Kabul, Afghanistan Afghanistan
Agha Khan univeristy hospital, Nairobi, Kenya Kenya
Lagos University Teaching Hospital, Lagos, Nigeria Nigeria
Umar Diabetes Foundation, Islamabad, Pakistan
National hospital Sri Lanka, Colombo, Colombo Sri Lanka
NHK, Kandy, Kandy Sri Lanka
Eligibility Criteria
Inclusion Criteria: Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2. Exclusion Criteria: Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 108
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Progression-free survival (Through the completion of the study, for an average of 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-10-06
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hellenic Cooperative Oncology Group
Contact Information
Study Contact:
Elena Fountzilas, MD, PhD
+306945779709
FOUNTZILA@ONCOGENOME.GR
Areti Stamboliou
+302106912520
a_stampoliou@hecog.ondsl.gr
Elena Fountzilas, MD
fountzila@oncogenome.gr
Hellenic Oncology Cooperative Group
Interventions
N/A
Study Locations (1 sites)
Hellenic Oncology Cooperative Group, Athens, Greece
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed HR-positive, HER2-negative breast cancer * Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology * 18 years or older * Any menopausal status * Treatment with abemaciclib in combination with endocrine therapy * Any endocrine therapy * At least two months of treatment with abemaciclib
Conditions Asthma in Children, Implementation, Pres...
Phase Not Applicable
Enrollment 500
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Despite a strong evidence-base for the efficacy of multilevel programs in reducing asthma symptoms among low-income preschool minority children, gaps remain in our understanding of how to best translate and scale up these efficacious interventions into sustainable programs that reduce known asthma health disparities. Head Start (HS) serves over one million low income children in the US each year by focusing on early learning, physical health, and family engagement. HS is committed to implementing evidence based programs to promote overall child well-being, and is focused on addressing asthma symptoms due to the deleterious impact on school absences and child development. We have demonstrated the effectiveness of a multi-level staff and family education program (ABC Asthma) that significantly reduced asthma symptoms and courses of oral corticosteroids. However, these interventions are not successfully integrated within community organizations for long-term sustainability. It is unknown how to best scale up and implement these evidence based asthma interventions into low resource community organizations that serve children at risk. Implementation strategies are frequently developed atheoretically and may not be tailored to the setting. The overall purpose of this project is to inform best practices of implementation of an asthma education program by 1) systematically evaluating the use of intervention mapping to develop a tailored implementation strategy in partnership with Head Start stakeholders, 2) examining both staff and organizational level determinants associated with implementation of ABC Asthma, and 3) evaluating the success of tailored implementation strategies on implementation outcomes and school absences and other health outcomes. The YMCA of Central Maryland have enthusiastically agreed to implement the Maryland ABC HS Asthma within 40 sites in four communities: Baltimore City, Baltimore County, Anne Arundel County, and Prince George's County.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • School Absences due to asthma symptoms (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-08-01
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Michelle Eakin, PhD (PRINCIPAL_INVESTIGATOR) - JHU
Contact Information
Study Contact:
Michelle Eakin, PhD
410-550-0487
meakin1@jhmi.edu
Interventions
N/A
Study Locations (2 sites)
Easter Seals Head Start Prince George's County, District Heights, Maryland 20747 United States
Y of Central Maryland Head Start, Nottingham, Maryland 21236 United States
Eligibility Criteria
Aim 1 Inclusion Criteria: * Aged 18 or older * Head Start Staff member or caregiver of child currently enrolled in Head Start with asthma * Cognitive ability to provide consent * Willing to be audio recorded
Conditions Non-Small Cell Lung Cancer, Head and Nec...
Phase PHASE1
Enrollment 694
Locations 48 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide. Participants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Azirkitug — Intravenous (IV) Infusion
  • Drug: Budigalimab — Intravenous (IV) Infusion
  • Drug: Bevacizumab — Intravenous (IV) Infusion
  • Drug: Telisotuzumab Adizutecan — Intravenous (IV) Infusion

Primary Outcomes

  • Number of Participants with Adverse Events (AE) (Up to 2 Years)
  • Maximum Observed Serum Concentration (Cmax) of Azirkitug (Up to 2 Years)
  • Time to Maximum Observed Serum Concentration (Tmax) of Azirkitug (Up to 2 Years)
  • Terminal Elimination Half-Life (t1/2) of Azirkitug (Up to 2 Years)
  • Area Under the Serum Concentration Versus Time Curve (AUC) of Azirkitug (Up to 2 Years)
  • Azirkitug Antidrug Antibody (ADA) (Up to 2 Years)
  • Azirkitug Neutralizing Antidrug Antibody (nADA) (Up to 2 Years)
  • Cmax of Budigalimab (Up to 2 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-11-01
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 694 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AbbVie
Principal Investigators:
  • ABBVIE INC. (STUDY_DIRECTOR) - AbbVie
Contact Information
Study Contact:
ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com
Site Coordinator
844-663-3742
Carolina BioOncology Institute /ID# 232597
Interventions
  • Drug: Azirkitug — Intravenous (IV) Infusion
  • Drug: Budigalimab — Intravenous (IV) Infusion
  • Drug: Bevacizumab — Intravenous (IV) Infusion
  • Drug: Telisotuzumab Adizutecan — Intravenous (IV) Infusion
Study Locations (48 sites)
City of Hope National Medical Center /ID# 276272, Duarte, California 91010 United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine, California 92618 United States
USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles, California 90033 United States
University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago, Illinois 60607 United States
University of Chicago Medical Center /ID# 276271, Chicago, Illinois 60637 United States
Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne, Indiana 46804 United States
Community Health Network, Inc. /ID# 243011, Indianapolis, Indiana 46250-2042 United States
Norton Cancer Institute /ID# 248903, Louisville, Kentucky 40241-2832 United States
START Midwest /ID# 248685, Grand Rapids, Michigan 49546-7062 United States
M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Inclusion Criteria: * Pre Treatment biopsy or archive tissue within 6 months without intervening treatment * Eastern Cooperative Oncology Group (ECOG) performance status of \<= 0 or 1 and a life expectancy of \>= 3 months. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) * Laboratory values meeting criteria outlined in the protocol * NSCLC - Advanced or metastatic progressed on standard of care (SOC) including chemotherapy and prior anti-PD-(L)1 antibody (separately or in combination). Actionable gene alterations are eligible if failed targeted therapeutic options. * HSNCC - Advanced/metastatic progressed on platinum and PD-1/PD-LI in recurrent or metastatic setting. * Micro Satellite Stable Colorectal Cancer (MSS-CRC) - Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Regorafenib and not MSI-h or MMR-deficient * Gastric and Gastroesophageal Junction adenocarcinoma (GEA) - Advanced/metastatic progressed on at least 1 prior cytotoxic chemotherapeutic regimen and if applicable immune checkpoint inhibitor and/or HER2 therapy * High-Grade Serous Ovarian Cancer (HGSOC) - Progressed serous epithelial ovarian, fallopian tube or primary peritoneal cancer post SOC and not eligible for surgical resection. Platinum resistant cannot have \>5 lines of prior therapy. * Pancreatic Adenocarcinoma (PDAC) - Advanced/metastatic progressed after SOC. Includes adenosquamous carcinoma and post-Whipple. * Triple Negative Breast Cancer (TNBC) - Progressed after 1 or 2 systemic therapy that must have included taxane and treatment naïve to immunotherapy targeting T-cell co-stimulation Exclusion Criteria: * Pancreatic Ductal Adenocarcinoma (PDAC) - Excludes neuroendocrine or acinar pancreatic carcinoma and participants with coagulopathy or at risk of or history of Deep vein thrombosis (DVT)/PE * No major surgery within 28 days prior to dosing * No active autoimmune/immunodeficiency disease with limited exceptions * Combination treatment excludes participants treated with anti-programmed cell death protein 1(PD-1)/Programmed cell death ligand 1 (PD-L1) who had immune mediated toxicity G3 or greater, interstitial lung disease, or hypersensitivity Combination treatment may also require no significant cardiac deficiencies and/or events * Pregnancy * Excluded medications include anticancer therapy within 5 half-live or 28 days (whichever is shorter), agent targeting Chemokine Receptor (CCR)8, live vaccines, immunosuppressive medication with limited exceptions
Conditions Advanced Malignant Solid Neoplasm, Metas...
Phase PHASE1
Enrollment 42
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). ZEN003694 is an oral medication with potential anticancer activity. It is an inhibitor of a family of proteins called bromodomain and extra-terminal (BET) which play important role during development and cellular growth. ZEN003694 may stop the growth of tumor cells that produce BET. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action proteins called MEK1 and MEK2, that signal cancer cells to multiply. It may help keep cancer cells from growing and spreading. There is pre-clinical evidence that using ZEN003694 and binimetinib together may shrink or stabilize cancers studied in this trial. There are two parts of this study; dose escalation and dose expansion. In the dose escalation part of this study, different people will get different doses of the study drugs ZEN003694 and binimetinib. In the dose expansion part of this study, the highest dose with manageable side effects will be given to additional people. This will help to understand the side effects that may happen with this drug combination.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BET Bromodomain Inhibitor ZEN-3694 — Given PO
  • Drug: Binimetinib — Given PO
  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Procedure: Computed Tomography — Undergo CT
  • Procedure: Magnetic Resonance Imaging — Undergo MRI

Primary Outcomes

  • Incidence of dose limiting toxicities (Part 1 [Dose Escalation]) (Up to 28 days from treatment start date)
  • Incidence of AEs (Part 2 [Dose Expansion]) (Up to 30 days after last treatment dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-08-02
Completion: 2027-03-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Sarina A Piha-Paul (PRINCIPAL_INVESTIGATOR) - University of Texas MD Anderson Cancer Center LAO
Contact Information
Study Contact:
Site Public Contact
866-632-6789
askmdanderson@mdanderson.org
UT MD Anderson Cancer Center
Sarina A. Piha-Paul
UT MD Anderson Cancer Center
Interventions
  • Drug: BET Bromodomain Inhibitor ZEN-3694 — Given PO
  • Drug: Binimetinib — Given PO
  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Procedure: Computed Tomography — Undergo CT
Study Locations (4 sites)
Boston Medical Center, Boston, Massachusetts 02118 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
University of Texas Medical Branch, Galveston, Texas 77555-0565 United States
UT MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Patients must have histologically confirmed advanced/metastatic or unresectable solid tumor that is refractory to standard therapy or has relapsed after standard therapy * Patients must have one of the following: * For Part 1 and 2 - * Triple negative breast cancer (TNBC) (estrogen receptor =\< 1%, progesterone receptor =\< 1%, human epidermal growth factor receptor 2 0-1+ or non-amplified) * Solid tumor with genomic alteration(s) activating RAS signaling including activating KRAS, NRAS, HRAS, or BRAF mutations, inactivating NF1 mutations, or BRAF fusions * Genomic alterations should be identified locally by next generation sequencing (NGS). Patient genomic reports will be reviewed by the MD Anderson Cancer Center (MDACC) Precision Oncology Decision Support team prior to initiation of study treatment * For Part 1, patients can have evaluable or measurable disease. For Part 2, patients must have measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Patients must be \>= 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C) or other investigational therapy to include hormonal, biological, or targeted agents; or at least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of study treatment initiation. Patients must be \>= 4 weeks beyond radiotherapy * Age \>= 18 years. Because no dosing or adverse events (AE) data are currently available on the use of binimetinib and ZEN003694 (ZEN-3694) in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 125,000/mcL * Hemoglobin \>= 8 g/dL or \>= 5.6 mmol/L * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) OR \< 2.0 x ULN in patients with documented Gilbert's syndrome * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN * Calculated creatinine clearance \>= 60 mL/min/1.73 m\^2 (based on the calculated Chronic Kidney Disease-Epidemiology collaboration \[CKD-EPI\] glomerular filtration rate estimation) * Prothrombin time =\< 1.5 x ULN * Partial thromboplastin time =\< 1.5 x ULN * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this study * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression by imaging for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to the first dose of study treatment. This exception does not include carcinomatous meningitis and primary CNS cancers, which are excluded regardless of clinical stability * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this study * Patients should be New York Heart Association Functional Classification of class 2B or better * Patients must have corrected QT (QTcF) \< 450 msec * The effects of ZEN003694 (ZEN-3694) and binimetinib on the developing human fetus are unknown. For this reason and because BETi agents are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after the completion of ZEN003694 (ZEN-3694) and binimetinib administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of ZEN003694 (ZEN-3694) and binimetinib administration * Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity who have a legally authorized representative (LAR) and/or family member available will also be eligible Exclusion Criteria: * Patients who have not recovered from adverse events (AEs) due to prior anticancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia, peripheral neuropathy, and endocrinopathy managed with replacement therapy before the initiation of study treatment * Patients who are receiving any other investigational agents * Breast cancer patients with a prior history of hormone receptor positivity will not be eligible * Patients with known PI3K pathway activating genomic alterations including inactivating mutations/deletions in PTEN and PIK3R1, amplifications in PIK3CA, and activating mutations in PIK3CA, Akt, or mTOR will not be eligible * Prior therapy with BET, RAF, MEK, or ERK inhibitor * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) and binimetinib * Patients requiring therapeutic doses of anticoagulation are excluded. Patients taking low-dose (prophylactic) anticoagulation (e.g., low-molecular weight heparin, low-dose warfarin, fondaparinux) are allowed. Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong inhibitors or inducers of CYP3A4 must be discontinued at least 7 days prior to the first dose of ZEN003694. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference (https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers). As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Patients with uncontrolled intercurrent illness * Patients with psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) and binimetinib are a BETi and MEK inhibitor agent, respectively, with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694) and binimetinib, breastfeeding should be discontinued if the mother is treated with ZEN003694 (ZEN-3694) and binimetinib * Patient has a history of cerebrovascular accident, myocardial infarction, or unstable angina within the previous 6 months prior to study treatment initiation * Patients with any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g., gastrectomy, ileal bypass, chronic diarrhea, gastroparesis) are excluded * Patient has a history of retinal vein occlusion * Patient has a history of pneumonitis or interstitial lung disease
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

If pulmonary hypertension is suspected, a right heart catheterization is usually performed to confirm or rule out the diagnosis. As part of this examination, blood samples are taken from various locations as standard and blood gas analyses are performed. One of the most important measurements during the right heart catheterization is the measurement of the pulmonary arterial occlusion pressure by the so-called wedge maneuver. To measure this value, the catheter with inflated balloon must be advanced into the pulmonary vessels until the "wedge" position is reached, i.e. the balloon completely occludes a branch of the pulmonary artery. In this study, the investigators want to characterize patients with pulmonary hypertension of different causes in more detail. To do that, two blood samples (totaling approximately 4 mL of blood, one sample directly after occlusion and the other one two minutes later) will be drawn during the right heart catheterization from the above-mentioned "wedge" position", behind the inflated balloon, and blood gas analyses will be performed on these samples. In addition, various clinical parameters (comorbidities, etc.) will be recorded by means of clinical questionnaires. Follow-up data will be analyzed and correlations with the aforementioned blood gas analyses will be examined. The results of the study will be used to more precisely characterize the still vague concept of secondary pulmonary hypertension. This could help to develop new therapeutic strategies in some subgroups in the future.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Blood gas analysis — Two blood samples will be drawn from the "wedge" position", behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later.

Primary Outcomes

  • Between group differences (At the time of recruitment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-06-25
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ayham Daher
Contact Information
Study Contact:
Ayham Daher, M.D.
+492418088763
adaher@ukaachen.de
University Hospital RWTH Aachen
Interventions
  • Diagnostic Test: Blood gas analysis — Two blood samples will be drawn from the "wedge" position", behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later.
Study Locations (1 sites)
University Hospital RWTH Aachen, Aachen, 52062 Germany
Eligibility Criteria
Inclusion Criteria: * Patients who have a clearly defined indication for Right heart catheterization. * Age \> 18 years * Informed consent for participation in the study will sign Exclusion Criteria: * Individuals who are not fully capable of giving consent and understanding the nature, significance, and scope of the study * Pregnancy and lactation * Wedge-BGA not possible
Conditions Asthma in Children
Phase PHASE2
Enrollment 320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To investigate whether high-dose vitamin D supplementation may have a beneficial effect on secondary prevention in preschool children (1-5 years of age), with respiratory infections being the primary cause of acute exacerbations with asthma-like symptoms.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Cholecalciferol D3 — 2000 IU of Vitamin D provided as oral suspension for one year
  • Other: Oral placebo suspension — Oral suspension with no active substance tasting like the active supplement.

Primary Outcomes

  • Number of acute exacerbations (One year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-10-01
Completion: 2031-10-01
Eligibility
Age: 12 Months and older
Sex: ALL
Volunteers: false
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen Studies on Asthma in Childhood
Principal Investigators:
  • Bo Chawes, MD, DMSc (PRINCIPAL_INVESTIGATOR) - chawes@copsac.com
Contact Information
Study Contact:
Klaus Bønnelykke, MD, PhD
+4538677360
kb@copsac.com
Ulrik Ralfkiaer, MSc, PhD
+4538674164
administration@dbac.dk
Klaus Bønnelykke, MD, PhD
+45 38677360
kb@copsac.com
University Hospital of Copenhagen
Interventions
  • Dietary Supplement: Cholecalciferol D3 — 2000 IU of Vitamin D provided as oral suspension for one year
  • Other: Oral placebo suspension — Oral suspension with no active substance tasting like the active supplement.
Study Locations (1 sites)
University Hospital of Copenhagen, Gentofte Municipality, Gentofte 2820 Denmark
Eligibility Criteria
Inclusion Criteria: The study population consists of children in the age group 1-5 years admitted to a pediatric ward, due to an acute episode with asthma-like symptoms. An acute asthma-like episode will be defined as annoying coughing, wheezing (wheezing or wheezing in connection with exhalation) and / or dyspnoea, which affects the child's well-being and requires hospitalization in a pediatric ward. Participation in the study requires that the child is in or has been in treatment with SABA, as monotherapy, or in combination with ICS, and possibly also in combination with LTRA in accordance with the Danish guidelines Exclusion Criteria: * The child is hospitalized with pneumonia * The child's daily intake of vitamin D supplementation is\> 400 IU / day (\~ 10 μg / day). * The child is given a combination of vitamin and dietary supplements containing vitamin D, thus the daily recommended dose is exceeded, as 2400 IU / day (\~ 60 μg / day) is accepted for children aged 1-4 years, as everyone here is recommended to take 400 IU / day (\~ 10 μg / day) by the Danish Health and Medicines Authority. * The baby has been exclusively breastfed for the past 6 months. * The child is malnourished * for children\> 2 years of age whose age-specific BMI is less than the 3rd percentile. * for children \<2 years, whose weight or height in relation to age is less than the 3rd percentile. * The child is a newly arrived refugee or immigrant from regions with a high risk of rickets. * The child has other chronic lung diseases. * The child is diagnosed with other conditions such as chronic lung disease, impaired renal function, neurological or psychiatric disorders, congenital or documented acquired QT prolongation, clinically relevant bradycardia, cardiac arrhythmia or severe heart failure and / or hepatic impairment. * The child is being treated with medication that alters calcium or vitamin D absorption / metabolism.
Conditions Natriuretic Peptides, Cardiovascular Dis...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Genetic Variants in the NPPA and NPPB gene of the Natriuretic Peptide family associated with the Cardiovascular and Metabolic Diseases (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-01-01
Completion: 2030-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Principal Investigators:
  • Pankaj Arora, MD, FAHA (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Nehal Vekariya, MS
205-934-7173
nvekariya@uabmc.edu
Nehal Vekariya, MS
205-934-7173
nvekariya@uabmc.edu
University of Alabama at Birmingham
Pankaj Arora, MD
University of Alabama at Birmingham
Interventions
N/A
Study Locations (1 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Eligibility Criteria
Inclusion Criteria: * Age more than or equal to 18 Exclusion Criteria: * Age \<18, at screening * Employees or students associated with the Division of Cardiovascular Disease at UAB will not be recruited due to their vulnerable status and susceptibility to coercion. * Women who are pregnant or who can become pregnant and not practicing an acceptable method of birth control.

Gut Microbiota in Metabolic Surgery

NCT05000996
Recruiting
Conditions Bariatric Surgery Candidate, Cardiovascu...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes. Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited. Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases. The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and/or tissue microbial features related to post-surgery cardiometabolic outcomes. In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery. Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation. Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery. Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery. This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Bariatric Surgery — Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)

Primary Outcomes

  • Estimated 10-year risk of atherosclerotic cardiovascular disease (From before surgery to 1 to 3-year after surgery to 10-year after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-08-19
Completion: 2035-01-01
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI)
Contact Information
Study Contact:
Danxia Yu, PhD
615-936-7389
danxia.yu@vumc.org
Charles R Flynn, PhD
615-343-8329
robb.flynn@vumc.org
Danxia Yu, PhD
6159367389
danxia.yu@vumc.org
Vanderbilt_University MC
Interventions
  • Procedure: Bariatric Surgery — Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
Study Locations (1 sites)
Vanderbilt_University MC, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center * Have a history of type 2 diabetes, hypertension, or dyslipidemia * Be able and willing to provide personal information and biological samples needed for the study Exclusion Criteria: * Prior gastric operations * A history of coronary artery disease, stroke, heart failure, HIV infection, or untreated viral hepatitis * Chemotherapy or radiotherapy for cancer within 2 years * Current inflammatory bowel disease or celiac disease * Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months

Aβ Dynamics in LLMD

NCT05004987
Recruiting
Conditions Alzheimer Disease, Major Depressive Diso...
Phase PHASE4
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis is that a reduction in depressive symptoms will be associated with a normalization of CSF AD biomarkers as well as peripheral inflammatory markers. This research would contribute to fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Escitalopram Oxalate — The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
  • Drug: Placebo — Daily dose of placebo will mimic that of ESC.

Primary Outcomes

  • Change in Cerebrospinal Fluid (CSF) Aβ40 Biomarker Levels (Baseline, Week 8)
  • Change in Cerebrospinal Fluid (CSF) Aβ42 Biomarker Levels (Baseline, Week 8)
  • Change in Vascular Dysfunction (VD) Biomarker Levels (Baseline, Week 8)
  • Change in Scores on Montgomery-Asberg Depression Ration Scale (MADRS) (Baseline, Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-02-04
Completion: 2027-06-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute on Aging (NIA)
Principal Investigators:
  • Nunzio Pomara, MD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Antero Sarreal, MD
845-398-6532
Antero.sarreal@nki.rfmh.org
Chelsea Reichert Plaska, PhD
845-398-5583
Chelsea.reichert@nki.rfmh.org
Nunzio Pomara, MD
NYU Langone Health
Interventions
  • Drug: Escitalopram Oxalate — The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
  • Drug: Placebo — Daily dose of placebo will mimic that of ESC.
Study Locations (2 sites)
NYU Langone Health, New York, New York 10016 United States
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962 United States
Eligibility Criteria
Inclusion Criteria: 1. Male and female subjects, age 60+ years inclusive, at the time of signing the informed consent. 2. Meeting Structured Clinical Interview (SCID-5-RV) for DSM-5 criteria for Major depressive disorder. 3. Montgomery-Åsberg Depression Rating Scale (MADRS) ≥18. 4. Have results of a physical examination, neurological examination, vitals, and EKG within normal limits at screening. 5. Cognitively unimpaired at screening visit as defined by Mini-Mental State Examination (MMSE) \>27. 6. Clinical Dementia Rating Scale (CDR) Global of 0\*. 7. A score of 85 or greater on the RBANS delayed memory index score. 8. Fluent in English, because some of the instruments used in this study have not been translated and validated in other languages, and are able to read at a 6th grade level or equivalent, as determined by the PI. 9. Medically stable with no significant cerebrovascular, neurological, or systemic disease expected to interfere with the study. 10. Adequate auditory acuity and normal-to-corrected vision. 11. Willing to undergo brain MRI, urine drug screen and blood sampling for routine laboratory testing, lumbar puncture, APOE genotyping and plasma drug levels. 12. Only individuals with normal or non-clinically significant abnormalities on routine laboratory tests, will be included. * If study partner is not available, the CDR will be skipped. Exclusion Criteria: 1. History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, or confluent (or more extensive) white matter hyperintensities. 2. Mental retardation, or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders). 3. Subjects with a Fazekas scale \>2. 4. Significant history of alcoholism or drug abuse in the past 2 years. Fulfilling SCID-5-RV/DSM-5 criteria for current or past diagnosis of any psychiatric disorder (e.g., schizophrenia, bipolar disorder, or any psychotic disorder) other than recurrent MDD or anxiety disorders (e.g., panic disorder, agoraphobia, etc.). 5. A current significant risk for suicidality based on the Columbia-Suicide-Severity Rating Scale (C-SSRS). 6. Insulin dependent diabetes. 7. Evidence of clinically relevant or unstable cardiac, pulmonary, endocrine or hematological conditions. 8. Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging. 9. Positive urine drug screen for illicit drugs. 10. History of poor tolerance to, poor response to, or ongoing treatment with escitalopram. 11. If taking antidepressants, currently taking fluoxetine, due to the length of time required to washout. 12. Treatment with following medications will not be permitted. In some cases, medications will be allowed if medically prescribed and dose regimen stable. Note: Some medications (e.g., amphetamines, opiates) may appear on the routine urine drug test in the screening period but can be allowed as per protocol. * For subjects taking prescribed psychoactive medications and supplements (i.e., opioids, amphetamines, amphetamine-like substances, and cannabinoids), must be on a stable dose for 1 month prior to randomization. * Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline). * Cholinesterase inhibitors and memantine * Continuous aspirin (any dosage) use which can affect platelet function is prohibited. Exception: If participant is on low dose aspirin for prophylaxis and is willing to temporarily discontinue prior to research blood draw (i.e., 2 days before). * Continuous use of other medications which are also known to affect platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs), anti-histamines. Exception: If participant is taking medication continuously and is willing to temporarily discontinue prior to research blood draw (i.e., 2 days before)